title: The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health.
abstract: OBJECTIVE
  The buprenorphine transdermal delivery system (BTDS) is indicated for reduction of pain in moderate to severe chronic low back pain (CLBP), which can affect patients' ability to perform routine activities of daily living (ADLs). This post hoc analysis of clinical trial data examines the impact of BTDS treatment on CLBP patients' ability to perform ADLs that relate to functioning with low back pain.
  
  
  METHODS
  Data are drawn from a multicenter, enriched enrollment, randomized, placebo-controlled, double-blind 12-week trial of BTDS for pain control among opioid-naive patients with moderate to severe CLBP. The 23 selected ADLs are those that (1) appear in the Low Back Pain Core Set of the International Classification of Functioning, Disability and Health and (2) link to the content of 3 patient-reported outcome instruments administered during the trial. Logistic regression models estimated the odds ratios (ORs) of BTDS patients' ability to perform each ADL at 12 weeks, controlling for baseline ability, relative to placebo.
  
  
  RESULTS
  The ORs for 10 ADLs related to sleeping, lifting, bending, and working reached multiplicity-adjusted statistical significance and indicated a greater ability to perform ADLs among BTDS users than among the placebo group. These 10 ORs ranged from 1.9 (no physical health-related restrictions on the kind of work performed) to 2.4 (being able to sleep undisturbed by pain).
  
  
  CONCLUSIONS
  These results suggest that for patients with moderate to severe CLBP, 12 weeks use of BTDS improves the ability to carry out certain ADLs related to sleeping, lifting, bending, and working.
authors.affiliation: *Optum, Lincoln, RI †Purdue Pharma LP, Stamford, CT ‡Department of Medicine, Johns Hopkins University, Baltimore, MD §Department of Anesthesiology, Georgetown University School of Medicine, Washington, DC ∥Department of Pharmacology, Temple University School of Medicine ¶Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA.
authors.forename: Kate
authors.initials: K
authors.lastname: Miller
authors.forename: Aaron
authors.initials: A
authors.lastname: Yarlas
authors.forename: Warren
authors.initials: W
authors.lastname: Wen
authors.forename: Bradley
authors.initials: B
authors.lastname: Dain
authors.forename: Shau Yu
authors.initials: SY
authors.lastname: Lynch
authors.forename: Steven R
authors.initials: SR
authors.lastname: Ripa
authors.forename: Joseph V
authors.initials: JV
authors.lastname: Pergolizzi
authors.forename: Robert
authors.initials: R
authors.lastname: Raffa
mesh_terms: D000203:Activities of Daily Living / Q000523:psychology*; D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000009:adverse effects*; D002047:Buprenorphine / Q000009:adverse effects*; D002908:Chronic Disease; D006233:Persons with Disabilities; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D038801:International Classification of Diseases; D016015:Logistic Models; D017116:Low Back Pain / Q000188:drug therapy* / Q000523:psychology*; D008297:Male; D010147:Pain Measurement; D012890:Sleep / Q000187:drug effects; D016896:Treatment Outcome; D016138:Walking; D014937:Work / Q000523:psychology
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine